The aim of this study was to evaluate whether results of surveillance for PDAC in high-risk individuals (HRI) differ between those with and without a pathogenic BRCA1/2 mutation. This prospective study was conducted within the Pancreatic Tumor Registry at a major cancer center. Read more . . .
Germline mutations in BRCA1/2 are risk factors for pancreatic ductal adenocarcinoma (PDAC).